Explainer

ADHD and Dopamine: What Brain Scans and Drug Studies Show

A 2024 review found limited evidence that ADHD is a low-dopamine disorder, and brain scans conflict: one meta-analysis found dopamine transporters 14% higher.

Mental Health Stats Research Team 7 min read

Key Takeaways

  • Dopamine is involved in ADHD, but a 2024 review of more than 40 years of research found limited evidence that low dopamine is a defining feature of the condition[1].40+ years[1]
  • A 2009 PET study of 53 unmedicated adults with ADHD and 44 controls found lower dopamine transporter and D2/D3 receptor markers in the brain's reward pathway[2].53 adults[2]
  • A meta-analysis of 9 PET and SPECT studies found striatal dopamine transporter density 14% higher on average in ADHD, and lower in people never treated with stimulants[3].14%[3]
  • Oral methylphenidate at an average dose of 0.8 mg/kg raised extracellular dopamine in the striatum of 11 healthy adults in a 2001 PET study[4].0.8 mg/kg[4]
  • The 2026 FDA label for Adderall XR states that the mode of therapeutic action in ADHD is not known[5].Not known[5]
  • The largest ADHD genome study, with more than 38,000 cases, found 27 significant signals, and no core dopamine gene ranked among the top risk genes[1].27 signals[1]
How these numbers are measured: There is no biological test for ADHD; diagnosis rests on symptom criteria[1]. Brain dopamine in living people is studied indirectly with PET and SPECT scans that track tracers binding to dopamine transporters or receptors, and small samples, prior stimulant use and different tracers help explain why studies disagree[1].

ADHD and Dopamine: Is ADHD Caused by Low Dopamine?

The link between ADHD and dopamine is real, but the popular version, that people with ADHD simply have too little dopamine, is not what the research shows. A 2024 review in Frontiers in Psychiatry covering more than 40 years of studies found evidence for dopamine's involvement but limited evidence for a low-dopamine state as a key component of ADHD[1].

The authors wrote that portraying ADHD as a general dopamine deficiency "might be one of the most common misconceptions" about its neurobiology[1]. NIMH's 2024 overview says researchers are not sure what causes ADHD, that genes appear to play a large role, and that it probably results from a combination of factors[6].

The dopamine hypothesis rests on four lines of evidence: stimulant drugs act on dopamine, animal models with altered dopamine genes show ADHD-like behavior, some brain scans implicate the dopamine system, and early gene studies flagged dopamine genes[1]. Skepticism is nearly as old. A 1987 review found that evidence from medications favored norepinephrine, a closely related brain chemical, over dopamine[1].

How many people have ADHD is a separate question, tracked on the ADHD statistics page and in How Many People Have ADHD?

Dopamine

Dopamine is a neurotransmitter, a chemical messenger that nerve cells use to signal one another. It is made from the amino acid tyrosine, acts on five receptor types (D1 to D5), and is cleared from the synapse by the dopamine transporter (DAT)[1]. Dopamine pathways reach the striatum, including the nucleus accumbens in the reward circuit, and the prefrontal cortex, a region involved in attention and memory[7][8].

Related Terms

dopamine transporter (DAT)
D2/D3 receptors
norepinephrine
catecholamines
striatum

Source: MacDonald et al., Frontiers in Psychiatry, 2024

What Brain Scans Show About Dopamine in ADHD

The strongest imaging evidence for a dopamine shortfall comes from a 2009 JAMA study at Brookhaven National Laboratory, where PET scans of 53 unmedicated adults with ADHD and 44 healthy controls found lower dopamine transporter and D2/D3 receptor binding in the reward pathway, including the nucleus accumbens and midbrain[2].

Those markers tracked symptoms. Attention ratings correlated with D2/D3 receptor availability in the accumbens (r = 0.35), and the authors linked reduced dopamine markers to inattention[2].

Other scans point the opposite way. A meta-analysis of 9 SPECT and PET studies, covering 169 people with ADHD and 173 matched controls, found striatal dopamine transporter density 14% higher in ADHD on average[3]. Some research groups read more transporters as faster dopamine clearance and lower dopamine tone[1].

Medication history mattered. Transporter density was higher in patients previously treated with stimulants and lower in those who had never taken them, which raises the possibility that part of the finding reflects adaptation to treatment rather than a cause of ADHD[3].

Across the imaging literature, the 2024 review found evidence for a decrease, an increase and no change in extracellular dopamine in ADHD compared with controls[1]. One task-based study it cites found lower background (tonic) dopamine release but stronger bursts (phasic release) in the caudate of people with ADHD, which may help reconcile the conflicting results[1].

Key Human Studies on Dopamine in ADHD

StudyDesignSampleMain finding
Volkow et al., 2009 (JAMA)PET scan53 adults with ADHD, 44 controlsLower DAT and D2/D3 binding in reward pathway
Fusar-Poli et al., 2012 (Am J Psychiatry)Meta-analysis of 9 PET/SPECT studies169 with ADHD, 173 controlsStriatal DAT 14% higher; varied with prior stimulant use
Plichta and Scheres, 2014 (Neurosci Biobehav Rev)Meta-analysis of 8 fMRI studiesN = 340Weaker ventral striatum response to anticipated reward (d = 0.48 to 0.58)
Volkow et al., 2001 (J Neurosci)PET scan after oral methylphenidate11 healthy adultsExtracellular dopamine rose; D2 availability fell 20%
MacDonald et al., 2024 (Front Psychiatry)Narrative review40+ years of studiesDopamine involved; limited evidence for a low-dopamine state

Selected human studies of dopamine and ADHD, with design, sample and main finding[2][3][7][4][1]

1DAT = dopamine transporter. PET and SPECT measure dopamine markers indirectly, and different groups have interpreted higher or lower transporter binding in opposite directions[1].

Sources

  • •Volkow et al., 2009
  • •Fusar-Poli et al., 2012
  • •Plichta and Scheres, 2014
  • •Volkow et al., 2001
  • •MacDonald et al., 2024
Average difference in striatal dopamine transporter density, ADHD vs. controls (9 PET/SPECT studies)
14% higher

Density was lower in people never treated with stimulants and higher in those previously treated, so the gap may partly reflect adaptation to medication rather than a cause of ADHD.

"Striatal dopamine transporter density was 14% higher on average in the ADHD group"

Fusar-Poli P, et al. (American Journal of Psychiatry)(2012) View Source

Dopamine, Reward and Motivation in ADHD

Much of the "dopamine-seeking" language around ADHD traces back to reward research. The ventral striatum, including the nucleus accumbens, is a hub of the brain's reward circuit and receives dopamine input from the midbrain[7].

A meta-analysis of 8 fMRI studies with 340 participants found a medium-sized reduction in ventral striatum activity while people with ADHD anticipated a reward (Cohen's d = 0.48 to 0.58)[7]. The 2009 PET study framed its own findings the same way, as a possible basis for reward and motivation deficits[2].

The pattern is not straightforward. In the general population, the same meta-analysis found the reverse: people with higher trait impulsivity showed stronger ventral striatum responses to reward[7]. Its authors concluded that too few studies existed for a final answer[7].

One framework described in the 2024 review is an inverted-U curve: prefrontal functions such as inhibitory control work best at a middle level of dopamine, and levels above or below that point impair them[1]. Under that model, the problem is regulation, not a simple shortage.

Do ADHD Genes Point to Dopamine?

Early candidate-gene studies linked ADHD to variants in dopamine genes, especially the dopamine transporter gene DAT1 (SLC6A3) and the D4 receptor gene DRD4[1]. Those studies used samples of hundreds of people, and later replication attempts gave inconsistent results[1].

Genome-wide association studies (GWAS) changed the picture. The largest, with more than 38,000 ADHD cases, found 27 significant genetic signals, yet none of the previously nominated candidate genes, dopamine genes included, ranked among the top risk genes[1]. ADHD risk variants were enriched, however, in genes expressed in midbrain dopamine neurons as well as in excitatory and inhibitory neurons[1].

ADHD is highly heritable, but its genetic risk is spread across many genes[1]. The twin and genome evidence is covered in Is ADHD Genetic?

What rare dopamine disorders show

Rare inherited diseases offer a natural test. People with conditions that sharply lower brain dopamine, such as dopamine transporter deficiency syndrome or tyrosine hydroxylase deficiency, mainly develop movement problems rather than typical ADHD symptoms[1].

Parkinson's disease, the best-known dopamine deficiency, produces slowed movement rather than hyperactivity, and the 2024 review concluded that its mechanisms are clearly distinct from those of ADHD[1].

How ADHD Medications Change Dopamine

Stimulant drugs are the main reason dopamine became tied to ADHD. NIMH describes stimulants as the most common type of ADHD medication and says they work by increasing levels of brain chemicals involved in thinking and attention[6]. Methylphenidate and amphetamines block dopamine and norepinephrine transporters, leaving more of both chemicals available at receptors[1].

A 2001 PET study measured the effect directly: oral methylphenidate at an average dose of 0.8 mg/kg significantly raised extracellular dopamine in the striatum of 11 healthy adults, shown by a 20% drop in available D2 receptors[4].

The authors proposed two explanations for the benefit: amplified dopamine signals could sharpen task-specific signaling and reduce distractibility, or could make a task more salient and interesting[4]. Drug classes, doses and trial results are compared in ADHD Meds: Stimulants vs. Non-Stimulants.

Amphetamines also increase the release of dopamine and norepinephrine. Even so, the Adderall XR label, revised in 2026, states that "the mode of therapeutic action in ADHD is not known"[5].

Non-stimulants complicate the low-dopamine story. Atomoxetine is selective for the norepinephrine transporter; in rat studies it tripled dopamine in the prefrontal cortex but did not change dopamine in the striatum or nucleus accumbens, unlike methylphenidate[8].

A good response to a stimulant also does not confirm ADHD. The 2024 review notes that stimulants have similar effects in most people whether or not they have the condition[1]. Diagnosis relies on symptom criteria and history, as described in how ADHD testing works.

How Common ADHD Medications Act on Dopamine

MedicationTypeMain actionDopamine effect in studies
MethylphenidateStimulantBlocks dopamine and norepinephrine transportersRaised striatal dopamine in human PET study
AmphetaminesStimulantBlocks reuptake and increases release of dopamine and norepinephrineRaises dopamine; ADHD mode of action not known per FDA label
AtomoxetineNon-stimulantSelective norepinephrine transporter inhibitorTripled prefrontal dopamine in rats; no striatal change

Mechanisms of three ADHD medications and their measured effects on dopamine[1][4][5][8]

1The atomoxetine dopamine finding comes from rat microdialysis, not human imaging[8].

Sources

  • •MacDonald et al., 2024
  • •Volkow et al., 2001
  • •FDA, 2026
  • •Bymaster et al., 2002

Can Dopamine Be Raised Naturally to Help ADHD?

Popular advice to "boost dopamine" with food, music, a "dopamine menu" or a "dopamine detox" is not supported by the studies reviewed here. None of them measured whether these habits change brain dopamine in people with ADHD.

Exercise has the most trial data, though those trials measure symptoms and thinking skills, not dopamine. A 2026 umbrella review in Psychiatry Research concluded that structured exercise may be a useful add-on to multimodal ADHD care but should not replace established treatments, and it rated the certainty of the evidence low to very low[9].

Diet links are indirect. Dopamine is built from tyrosine, and inherited disorders of amino acid metabolism, such as phenylketonuria, have been linked to ADHD-like problems with executive function[1]. Those findings involve rare metabolic diseases, not everyday diets.

What Researchers Think Now: Beyond Low Dopamine

The 2024 review suggests that dopamine changes may be present only in a subset of people with ADHD, and that identifying those subgroups could help tailor treatment[1]. It also points to dopamine's interactions with norepinephrine and serotonin, which are hard to study in isolation[1].

Other reviews it cites find greater consensus on different mechanisms, such as weaker prefrontal connectivity and lower prefrontal glucose metabolism[1]. The World Federation of ADHD's 2021 consensus statement, built on 208 empirically supported statements, did not single out dopamine as a key neurotransmitter[1].

Social media has carried the simpler version. A study cited in the review found that 52% of the 100 most popular TikTok videos about ADHD were misleading[1].

Frequently Asked Questions

Sources & References

  1. MacDonald HJ, Kleppe R, Szigetvari PD, Haavik J. The dopamine hypothesis for ADHD: an evaluation of evidence accumulated from human studies and animal models. Frontiers in Psychiatry. Published 2024. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11604610/ [Link]
  2. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. Published 2009. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC2958516/ [Link]
  3. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. American Journal of Psychiatry. Published 2012. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/22294258/ [Link]
  4. Volkow ND, Wang GJ, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. Journal of Neuroscience. Published 2001. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/11160455/ [Link]
  5. U.S. Food and Drug Administration. Adderall XR prescribing information. FDA. Published 2026. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021303s040lbl.pdf [Link]
  6. National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder: What You Need to Know. NIMH. Published 2024. Accessed October 2026. https://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-what-you-need-to-know [Link]
  7. Plichta MM, Scheres A. Ventral-striatal responsiveness during reward anticipation in ADHD and its relation to trait impulsivity in the healthy population: a meta-analytic review of the fMRI literature. Neuroscience and Biobehavioral Reviews. Published 2014. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC3989497/ [Link]
  8. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. Published 2002. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/12431845/ [Link]
  9. Zhu F, Zhang X, Wu Y, et al. Physical exercise interventions for health outcomes in children and adolescents with attention deficit hyperactivity disorder: an umbrella review with meta-analysis. Psychiatry Research. Published 2026. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/42284935/ [Link]

Related Statistics